{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:32:48Z","timestamp":1767648768273},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Encapsulating-peritoneal-sclerosis (EPS) is a rare, but serious and life-threatening complication of peritoneal dialysis (PD). Treatment of EPS consists of discontinuation of PD and maintenance of nutritional status, whereas the role of corticosteroids, tamoxifen and other immunosuppresive agents is not yet fully elucidated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case-presentation<\/jats:title>\n                <jats:p>We report the case of a 28-year-old patient, who developed a severe form of calcifying EPS after a 6-year-long therapy with automated PD. The clinical presentation was severe with repeated episodes of total bowel obstruction, weight loss and malnutrition that mandated his prolonged hospitalization. Initial treatment included corticosteroids and tamoxifen (20\u2009mg\/day) with a clinically meaningful improvement in gastrointestinal function and nutritional status over the first 6\u201312\u2009months. Corticosteroids were discontinued at 18\u2009months, but owing to persistence of calcifying lesions and peritoneal thickening in repeated computed-tomography (CT) scans, tamoxifen remained unmodified at a low-dose of 20\u2009mg\/day for a 10-year-long period. During follow-up, the patient remained symptoms-free in an excellent clinical condition and the CT findings were unchanged.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Long-term administration of tamoxifen was not accompanied by any drug-related adverse effects and potentially exerted a beneficial action on down-regulation of inflammatory and fibrotic processes and improvement of gastrointestinal function, nutritional status and overall health-related quality of life.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-020-01769-x","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T17:03:14Z","timestamp":1585674194000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["10-year-long survival in a PD patient with severe calcifying encapsulating peritoneal sclerosis treated with tamoxifen: a case-report"],"prefix":"10.1186","volume":"21","author":[{"given":"Vassilios","family":"Liakopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis I.","family":"Georgianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Vaios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanos","family":"Roumeliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Karligkiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantelis E.","family":"Zebekakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrneph.2011.93","volume":"7","author":"MR Korte","year":"2011","unstructured":"Korte MR, Sampimon DE, Betjes MG, Krediet RT. Encapsulating peritoneal sclerosis: the state of affairs. Nat Rev Nephrol. 2011;7:528\u201338.","journal-title":"Nat Rev Nephrol"},{"key":"1769_CR2","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.2215\/CJN.01260209","volume":"4","author":"MC Brown","year":"2009","unstructured":"Brown MC, Simpson K, Kerssens JJ, Mactier RA. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol. 2009;4:1222\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ki.2010.16","volume":"77","author":"DW Johnson","year":"2010","unstructured":"Johnson DW, Cho Y, Livingston BE, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int. 2010;77:904\u201312.","journal-title":"Kidney Int"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"e0190079","DOI":"10.1371\/journal.pone.0190079","volume":"13","author":"CC Tseng","year":"2018","unstructured":"Tseng CC, Chen JB, Wang IK, et al. Incidence and outcomes of encapsulating peritoneal sclerosis (EPS) and factors associated with severe EPS. PLoS One. 2018;13:e0190079.","journal-title":"PLoS One"},{"key":"1769_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ndt\/gfv440","volume":"31","author":"MR Lambie","year":"2016","unstructured":"Lambie MR, Chess J, Summers AM, Williams PF, Topley N, Davies SJ. Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL fluid study. Nephrol Dial Transplant. 2016;31:480\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/ndt\/gfp008","volume":"24","author":"G Balasubramaniam","year":"2009","unstructured":"Balasubramaniam G, Brown EA, Davenport A, et al. The pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24:3209\u201315.","journal-title":"Nephrol Dial Transplant"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3747\/pdi.2017.00018","volume":"37","author":"EA Brown","year":"2017","unstructured":"Brown EA, Bargman J, van Biesen W, et al. Length of time on peritoneal Dialysis and encapsulating peritoneal sclerosis - position paper for ISPD: 2017 update. Perit Dial Int. 2017;37:362\u201374.","journal-title":"Perit Dial Int"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/ndt\/14.5.1343b","volume":"14","author":"RM Fagugli","year":"1999","unstructured":"Fagugli RM, Selvi A, Quintaliani G, Bianchi M, Buoncristiani U. Immunosuppressive treatment for sclerosing peritonitis. Nephrol Dial Transplant. 1999;14:1343\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1769_CR9","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1053\/j.ajkd.2007.07.036","volume":"51","author":"JP Lafrance","year":"2008","unstructured":"Lafrance JP, Letourneau I, Ouimet D, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis. 2008;51:e7\u201310.","journal-title":"Am J Kidney Dis"},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/089686080502500312","volume":"25","author":"CF Wong","year":"2005","unstructured":"Wong CF, Beshir S, Khalil A, Pai P, Ahmad R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int. 2005;25:285\u20137.","journal-title":"Perit Dial Int"},{"issue":"Suppl 4","key":"1769_CR11","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1177\/089686080502504S06","volume":"25","author":"H Kawanishi","year":"2005","unstructured":"Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25(Suppl 4):S39\u201347.","journal-title":"Perit Dial Int"},{"key":"1769_CR12","first-page":"60","volume":"22","author":"H Kawanishi","year":"2006","unstructured":"Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial. 2006;22:60\u20134.","journal-title":"Adv Perit Dial"},{"key":"1769_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/ndt\/gfs159","volume":"28","author":"J Latus","year":"2013","unstructured":"Latus J, Ulmer C, Fritz P, et al. Encapsulating peritoneal sclerosis: a rare, serious but potentially curable complication of peritoneal dialysis-experience of a referral Centre in Germany. Nephrol Dial Transplant. 2013;28:1021\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.surg.2012.07.033","volume":"153","author":"C Ulmer","year":"2013","unstructured":"Ulmer C, Braun N, Rieber F, et al. Efficacy and morbidity of surgical therapy in late-stage encapsulating peritoneal sclerosis. Surgery. 2013;153:219\u201324.","journal-title":"Surgery."},{"key":"1769_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3747\/pdi.2010.00118","volume":"31","author":"N Braun","year":"2011","unstructured":"Braun N, Fritz P, Biegger D, et al. Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum--implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int. 2011;31:291\u2013300.","journal-title":"Perit Dial Int"},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000322255","volume":"31","author":"JW Huang","year":"2011","unstructured":"Huang JW, Yen CJ, Wu HY, et al. Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis. Blood Purif. 2011;31:252\u20138.","journal-title":"Blood Purif"},{"key":"1769_CR17","doi-asserted-by":"publisher","unstructured":"Yan P, Tang H, Chen X, et al. Tamoxifen attenuates dialysate-induced peritoneal fibrosis by inhibiting GSK-3beta\/beta-catenin axis activation. Biosci Rep. 2018;38(6). https:\/\/doi.org\/10.1042\/BSR20180240.","DOI":"10.1042\/BSR20180240"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"e61165","DOI":"10.1371\/journal.pone.0061165","volume":"8","author":"J Loureiro","year":"2013","unstructured":"Loureiro J, Sandoval P, del Peso G, et al. Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS One. 2013;8:e61165.","journal-title":"PLoS One"},{"key":"1769_CR19","first-page":"395","volume":"12","author":"PM Allaria","year":"1999","unstructured":"Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol. 1999;12:395\u20137.","journal-title":"J Nephrol"},{"key":"1769_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3747\/pdi.2012.00286","volume":"34","author":"E De Sousa-Amorim","year":"2014","unstructured":"De Sousa-Amorim E, del Peso G, Bajo MA, et al. Can EPS development be avoided with early interventions? The potential role of tamoxifen--a single-center study. Perit Dial Int. 2014;34:582\u201393.","journal-title":"Perit Dial Int"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/089686080602600215","volume":"26","author":"MA Eltoum","year":"2006","unstructured":"Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int. 2006;26:203\u20136.","journal-title":"Perit Dial Int"},{"key":"1769_CR22","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ndt\/gfq362","volume":"26","author":"MR Korte","year":"2011","unstructured":"Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MG. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch multicentre EPS study. Nephrol Dial Transplant. 2011;26:691\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"1769_CR23","first-page":"104","volume":"22","author":"A Poultsidi","year":"2006","unstructured":"Poultsidi A, Liakopoulos V, Eleftheriadis T, Zarogiannis S, Bouchlariotou S, Stefanidis I. Gross calcification of the small bowel in a continuous ambulatory peritoneal dialysis patient with sclerosing peritonitis. Adv Perit Dial. 2006;22:104\u20137.","journal-title":"Adv Perit Dial"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst. 2005;97:1652\u201362.","journal-title":"J Natl Cancer Inst"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-01769-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T23:08:12Z","timestamp":1617145692000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01769-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"7 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}